David Ure, Chief Executive Officer & Founder: Mr. Ure is Inanovate’s Chief Executive Officer and co-inventor of the Longitudinal Assay Screening technology. He founded Inanovate and is responsible for all aspects of the Company’s strategy and execution, including leading the development and implementation of Inanovate’s products and partnering relationships. Mr. Ure was previously an entrepreneur in the financial consulting industry and has spent the last fifteen years in executive roles within Life Science and management consulting industries. Mr. Ure holds a Bachelor of Science with honors in Astrophysics, a Master of Science with Distinction in Radiation Physics from the University of Birmingham, U.K., and a MBA Summa Cum Laude, from Babson College, US.
Matthey Kostura, Chief Science Officer: Dr. Kostura has over 25 years of senior management and technical experience in developing and evaluating advanced technologies for bio-molecule screening applications. Prior roles include: Manager of High Throughput Biology at GlaxoSmithKline, and Sr. Vice President of Research and Development at TransTech Pharma. Dr. Kostura has led the deployment and sponsored the development of multiple immunoassay technologies suitable for use in the research environment, and has experience in the development of immunoassays used in both GMP and GLP environments. Dr. Kostura holds a PhD in Biology from University of Maryland and undertook post-doc work at Cold Spring Harbor Laboratories.
James Nelson, Ph.D. Chief Technology Officer: Dr. Nelson is Inanovate’s Chief Technology Officer and co-inventor of the Longitudinal Assay Screening technology. He oversees the development and implementation of the Company’s technology strategy, leading the development work on the Bio-ID. Dr. Nelson has over 16 years experience in developing and establishing advanced technologies for biomolecule screening, including 10 years as Manager of Technology Development at GlaxoSmithKline where he ran an interdisciplinary team on the development and optimization of next generation multiplexing technologies. Dr. Nelson holds a Bachelor of Science in Chemistry from the Florida State University and a PhD in Organic Chemistry from the University of Illinois.
Greg Votaw, VP of Engineering: Mr Votaw is Inanovate’s Vice President of Engineering. He is responsible for the development, manufacturing and optimization of Inanovate’s Bio-ID systems. Mr Votaw has over 16 years experience developing and implementing automation systems for the pharmaceutical industry and managing projects from concept through R&D and installation at research sites worldwide. He is a specialist in micro fluidics and automation systems with six issued patents and peer-reviewed papers. Mr Votaw holds an AE in Electronics Engineering; and was three-time recipient of Scientific Excellence Award at GlaxoSmithKline.
Robert Nelson, VP of Operations: Mr Nelson coordinates, leads and implements Inanovate’s operational strategy. Central to his role os the development and implementation of scalable manufacturing procedures for the Bio-ID’s disposable micro-fluidic cartridges. Mr Nelson has over 20 years experience in development and manufacturing process control of micro-fluidic systems, including executive and senior management positions at Dakota BioSciences, Picogram, Inc, Amersham Biosciences and Aclara. Mr Nelson holds a BS in Chemistry and an MS in Forensic Chemistry from Northeastern University.